Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Landos Biopharma Inc (NQ: LABP ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, May 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Landos Biopharma Inc LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP May 11, 2024 From Kahn Swick & Foti, LLC Via Business Wire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN) April 01, 2024 From Brodsky & Smith LLC Via GlobeNewswire LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP March 27, 2024 From Kahn Swick & Foti, LLC Via Business Wire LABP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Landos Biopharma, Inc. Is Fair to Shareholders March 25, 2024 From Halper Sadeh LLC Via Business Wire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE) March 25, 2024 From Brodsky & Smith LLC Via GlobeNewswire Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ Founder February 28, 2023 From Landos Biopharma, Inc. Via GlobeNewswire Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn’s and Colitis Organization January 11, 2023 Company Remains On-Track to Initiate Phase 2 Proof-of-Concept Clinical Trial in Second Quarter of 2023 From Landos Biopharma, Inc. Via GlobeNewswire Landos Biopharma Provides Comprehensive Update on Clinical Development Plans January 05, 2023 From Landos Biopharma, Inc. Via GlobeNewswire Landos Biopharma Announces $16.7 Million Private Placement Financing January 05, 2023 From Landos Biopharma, Inc. Via GlobeNewswire Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update November 10, 2022 On Track to Complete Comprehensive Review of Clinical Development Plans in the Coming Weeks From Landos Biopharma, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
